Infliximab treatment shifts the balance between stimulatory and inhibitory Fcγ receptor type II isoforms on neutrophils in patients with rheumatoid arthritis
| العنوان: | Infliximab treatment shifts the balance between stimulatory and inhibitory Fcγ receptor type II isoforms on neutrophils in patients with rheumatoid arthritis |
|---|---|
| المؤلفون: | Luminita Pricop, Ani Aydin, Patricia Redecha, Melanie J. Harrison, Jane E. Salmon, Kristina Belostocki, Linda Leff |
| المصدر: | Arthritis & Rheumatism. 58:384-388 |
| بيانات النشر: | Wiley, 2008. |
| سنة النشر: | 2008 |
| مصطلحات موضوعية: | Adult, Male, Neutrophils, medicine.medical_treatment, Blotting, Western, Immunology, Inflammation, Antigen-Antibody Complex, Arthritis, Rheumatoid, Immune system, Rheumatology, Antigens, CD, Immunopathology, medicine, Humans, Immunology and Allergy, Pharmacology (medical), Receptor, Tumor Necrosis Factor-alpha, business.industry, Receptors, IgG, Antibodies, Monoclonal, Middle Aged, Flow Cytometry, medicine.disease, Infliximab, Cytokine, Antirheumatic Agents, Rheumatoid arthritis, Female, Tumor necrosis factor alpha, medicine.symptom, business, medicine.drug |
| الوصف: | Human neutrophils express both activating and inhibitory Fcgamma receptors (FcgammaR), and their relative expression determines the inflammatory response to immune complexes. Tumor necrosis factor alpha (TNFalpha) up-regulates the expression of stimulatory FcgammaRIIa on neutrophils in vitro, and amplifies immune complex-induced activation of neutrophils in vivo. This study was undertaken to determine whether TNFalpha blockade in patients with rheumatoid arthritis (RA) alters the balance of activating FcgammaR and inhibitory FcgammaR and thereby decreases inflammation.We used fluorescence-activated cell sorting and Western blotting to examine FcgammaR expression on neutrophils in 24 patients with RA, preceding their first infusion of infliximab and immediately prior toor=3 subsequent infusions.In 13 of 24 patients (54.2%), there was a decrease in the expression of the predominant activating FcgammaR, FcgammaRIIa, after treatment with infliximab, an effect that persisted overor=3 months of treatment. Although prior to initiation of infliximab therapy the inhibitory FcgammaR, FcgammaRIIb, was undetectable in neutrophils from 23 of 24 patients with RA, FcgammaRIIb protein was detected by Western blotting in 9 patients (37.5%) at the time of the third infliximab infusion. The induction of inhibitory FcgammaRIIb was always associated with decreased levels of FcgammaRIIa, and improvement following infliximab therapy, measured using the Health Assessment Questionnaire, was significantly associated with down-regulation of FcgammaRIIa.Our findings indicate that TNFalpha inhibition may reduce inflammation in patients with RA by restoring the balance of activating and inhibitory FcgammaR and thereby raising the threshold for immune complex-mediated activation of neutrophils. |
| تدمد: | 1529-0131 0004-3591 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5797841579dcb8efac509fd37bdc5898Test https://doi.org/10.1002/art.23200Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....5797841579dcb8efac509fd37bdc5898 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15290131 00043591 |
|---|